ImmunoPrecise Antibodies Future Growth
Future criteria checks 4/6
ImmunoPrecise Antibodies is forecast to grow earnings and revenue by 72.8% and 19.7% per annum respectively while EPS is expected to grow by 73.5% per annum.
Key information
72.8%
Earnings growth rate
73.5%
EPS growth rate
Life Sciences earnings growth | 26.2% |
Revenue growth rate | 19.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 18 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
4/30/2027 | 42 | -1 | N/A | N/A | 1 |
4/30/2026 | 34 | -6 | N/A | N/A | 1 |
4/30/2025 | 25 | -13 | N/A | N/A | 2 |
7/31/2024 | 24 | -28 | -7 | -6 | N/A |
4/30/2024 | 25 | -27 | -6 | -4 | N/A |
1/31/2024 | 24 | -14 | -5 | -4 | N/A |
10/31/2023 | 23 | -16 | -8 | -7 | N/A |
7/31/2023 | 22 | -21 | -12 | -10 | N/A |
4/30/2023 | 21 | -27 | -21 | -20 | N/A |
1/31/2023 | 20 | -26 | -21 | -19 | N/A |
10/31/2022 | 20 | -25 | -23 | -21 | N/A |
7/31/2022 | 19 | -23 | -20 | -19 | N/A |
4/30/2022 | 19 | -17 | -11 | -10 | N/A |
1/31/2022 | 19 | -17 | -10 | -9 | N/A |
10/31/2021 | 19 | -15 | -6 | -4 | N/A |
7/31/2021 | 19 | -10 | -4 | -2 | N/A |
4/30/2021 | 18 | -7 | -2 | -1 | N/A |
1/31/2021 | 17 | -3 | -1 | 1 | N/A |
10/31/2020 | 17 | -3 | 0 | 1 | N/A |
7/31/2020 | 15 | -3 | -1 | -1 | N/A |
4/30/2020 | 14 | -5 | -2 | -1 | N/A |
1/31/2020 | 13 | -8 | -3 | -3 | N/A |
10/31/2019 | 11 | -8 | -4 | -3 | N/A |
7/31/2019 | 11 | -9 | -4 | -3 | N/A |
4/30/2019 | 11 | -8 | -4 | -3 | N/A |
1/31/2019 | 10 | -6 | -4 | -3 | N/A |
10/31/2018 | 9 | -6 | -4 | -3 | N/A |
7/31/2018 | 8 | -5 | -3 | -2 | N/A |
4/30/2018 | 5 | -5 | N/A | -3 | N/A |
1/31/2018 | 4 | -4 | N/A | -3 | N/A |
10/31/2017 | 3 | -7 | N/A | -3 | N/A |
7/31/2017 | 2 | -6 | N/A | -2 | N/A |
4/30/2017 | 3 | -5 | N/A | -1 | N/A |
1/31/2017 | 3 | -4 | N/A | 0 | N/A |
10/31/2016 | 3 | 1 | N/A | 1 | N/A |
7/31/2016 | 2 | 0 | N/A | 0 | N/A |
4/30/2016 | 2 | 0 | N/A | 0 | N/A |
4/30/2015 | 2 | 0 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TQB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: TQB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TQB is expected to become profitable in the next 3 years.
Revenue vs Market: TQB's revenue (19.7% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: TQB's revenue (19.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TQB's Return on Equity is forecast to be high in 3 years time